Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
JERUSALEM – August 9th, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of
orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.
"We continue to deliver strong execution with key milestones achieved during the second quarter of 2024 across each of our N-Tab™ oral
peptide programs dedicated to patients with OBGYN/endocrinology, GI and metabolic diseases” said Miranda Toledano, Entera’s CEO. “Importantly, we are now just five months away from FDA’s potential landmark ruling on the ASBMR-FNIH SABRE regulatory
endpoint for osteoporosis drugs, which we view as a major catalyst for EB613. We are especially keen to start our pivotal study of EB613 in a much wider population where injectable anabolic drugs do not play a dominant role. Because of its potential
dual mechanism of action, faster onset of action as an anabolic boosting agent and oral minitablet format, we believe EB613 is uniquely positioned to support earlier osteoanabolic intervention in post-menopausal women at high risk of fracture,” she
added.
EB613: First Oral PTH(1-34) Daily Osteoanabolic Tablets for Osteoporosis
|
• |
In April 2024, the Journal of Bone and Mineral Research (JBMR) published “Oral daily PTH(1-34) Tablets [EB613] in Postmenopausal Women
with Low BMD or Osteoporosis: A Randomized, Placebo-Controlled, 6-Month, Phase 2 Study”
|
|
• |
In May 2024, Entera welcomed Dr. Rachel Wagman as Key Clinical Advisor to lead EB613 clinical development. Wagman has successfully advanced the development of five molecules, including the
osteoporosis products Forteo®, Prolia® and Evenity® through registration
|
|
• |
In June 2024, the JMBR published an independent editorial titled “A Novel Oral hPTH(1-34) [EB613] Unveils the Promise of Modeling-Based Anabolism with No
Increase in Bone Remodeling”
|
|
• |
In July 2024, Entera announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was
selected for presentation at the ASBMR September 2024 Annual Meeting in Toronto
|
|
• |
In July 2024, Entera announced that the SABRE (Study to Advance BMD as a Regulatory Endpoint) is expected to provide an update at the ASBMR September 2024 Annual Meeting in
Toronto
|
EB612: First Oral PTH(1-34) Peptide Replacement Therapy Tablets for Hypoparathyroidism
|
• |
In June 2024, Entera presented Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, at the Endocrine Society ENDO 2024 Annual Meeting. Entera showed
that the data supports potentially moving the BID (twice-daily) tablet dose to Phase 2 development in patients with hypoparathyroidism
|
|
• |
Entera continues to collaborate with a third party on the development of another PTH replacement treatment for hypoparathyroidism
|
First GLP-2 Peptide Tablets for Short Bowel Syndrome
|
• |
In March 2024, Entera announced positive in vivo PK results from its program combining OPKO Health, Inc.’s (Nasdaq: OPK) long acting GLP-2 analogue with N-Tab™ technology. Pharmacology data
is expected early in the second half of 2024
|
First GLP-1/Glucagon Agonist (Oxyntomodulin) Peptide Tablets for Obesity
|
• |
Collaborative work is ongoing combining N-Tab™ with OPKO’s long-acting Oxyntomodulin (OXM) analogues for potential treatment for obesity and other metabolic diseases. PK
data for the oral OXM tablet are expected early in the second half of 2024
|
Financial Results for the Quarter Ended June 30, 2024
As of June 30,2024, Entera had cash and cash equivalents of $9.1 million. The Company expects that its existing cash
resources are sufficient to meet its projected operating requirements into the third quarter of 2025.
Research and development expenses for the three months ended June 30, 2024 were $1.1 million, as compared to $1.2
million for the three months ended June 30, 2023. The decrease of $0.1 million was primarily due to a decrease of $0.3 million in clinical expenses for our Phase 1 PK study related to our new generation platform and new formulations for EB612, which
completed its first stage in 2023.
General and administrative expenses for both the three months ended June 30, 2024 and 2023 were $1.1 million.
Operating expenses for the period ended June 30, 2024 were $2.2 million, as compared to $2.3 million for the quarter ended June 30, 2023.
Net loss was $2.1 million, or $0.06 per ordinary share (basic and diluted), for the quarter ended June 30, 2024, as compared to $2.3
million, or $0.08 per ordinary share (basic and diluted), for the quarter ended June 30, 2023.
About Entera Bio
Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs
where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab™) and its pipeline includes five differentiated, first-in-class oral peptide programs,
expected to enter the clinic (Phase 1 to Phase 3) by 2025. The Company’s most advanced product candidate, EB613 (oral PTH (1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal
women with low BMD and high-risk osteoporosis, with no prior fracture. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to
initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint which is expected to occur by January 2025. The EB612 program is being developed as the first oral PTH(1-34) tablet peptide
replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet as an injection-free
alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook,
Instagram.
Contact:
Entera Bio:
Ms. Miranda Toledano
Chief Executive Officer
Entera Bio
Email: miranda@enterabio.com
Cautionary Statement Regarding Forward Looking Statements
Various statements in this press release are “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute
forward-looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,”
and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and
uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.
Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking
statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and
planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains;
loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the
size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s expectations regarding
licensing, business transactions and strategic collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability
to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United
States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statements Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the SEC, as well as the company’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no
assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information
in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except
to the extent required by law.
|
ENTERA BIO LTD.
|
|
CONSOLIDATED BALANCE SHEETS
|
|
(U.S. dollars in thousands)
|
| |
|
June 30,
|
|
|
December 31,
|
|
| |
|
2024
|
|
|
2023
|
|
| |
|
(Unaudited)
|
|
|
(Audited)
|
|
| |
|
|
|
|
Cash and cash equivalents
|
|
|
9,056
|
|
|
|
11,019
|
|
|
Accounts receivable and other current assets
|
|
|
539
|
|
|
|
238
|
|
|
Property and equipment, net
|
|
|
76
|
|
|
|
100
|
|
|
Other assets, net
|
|
|
364
|
|
|
|
408
|
|
|
Total assets
|
|
|
10,035
|
|
|
|
11,765
|
|
| |
|
|
|
|
|
|
|
|
|
Accounts payable and other current liabilities
|
|
|
1,294
|
|
|
|
1,091
|
|
|
Total non-current liabilities
|
|
|
219
|
|
|
|
288
|
|
|
Total liabilities
|
|
|
1,503
|
|
|
|
1,379
|
|
|
Total shareholders' equity
|
|
|
8,532
|
|
|
|
10,386
|
|
| |
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders' equity
|
|
|
10,035
|
|
|
|
11,765
|
|
ENTERA BIO LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)
(Unaudited)
| |
|
Three Months Ended
June 30,
|
|
| |
|
|
|
|
|
|
|
REVENUES
|
|
|
57
|
|
|
|
-
|
|
|
COST OF REVENUES
|
|
|
48
|
|
|
|
-
|
|
|
GROSS PROFIT
|
|
|
9
|
|
|
|
-
|
|
|
OPERATING EXPENSES:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
1,086
|
|
|
|
1,209
|
|
|
General and administrative
|
|
|
1,088
|
|
|
|
1,135
|
|
|
Other income
|
|
|
|
|
|
|
|
|
|
TOTAL OPERATING EXPENSES
|
|
|
|
|
|
|
|
|
|
OPERATING LOSS
|
|
|
|
|
|
|
|
|
|
FINANCIAL INCOME, NET
|
|
|
|
|
|
|
|
|
|
NET LOSS
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
LOSS PER SHARE BASIC AND DILUTED
|
|
|
|
|
|
|
|
|
|
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
|
|
|
|
|
|
|
|
|